Compared side by side
Cagrilintide vs eloralintide: how they differ
The short answer
Both are weekly amylin drugs, built differently: cagrilintide acts on amylin receptors and on the calcitonin receptor, while eloralintide, from Eli Lilly, acts far more on amylin receptors than on the calcitonin receptor, and its half-life of about 14 days keeps levels nearly flat across the week. Neither is approved: cagrilintide is the amylin half of Novo Nordisk’s CagriSema, and eloralintide has been in phase 3 since late 2025. On their own, cagrilintide’s higher doses led to about 10–12% weight loss in trials, and eloralintide’s ran from about 9.5% on 1 mg to about 20% on 9 mg at 48 weeks in phase 2.
Side by side
| Compared | Cagrilintide | Eloralintide |
|---|---|---|
| Category | Metabolic & GLP-1 | Metabolic & GLP-1 |
| Also known as | Cagri, AM833, NNC0174-0833 | LY3841136, Elora |
| What it is | A long-acting version of amylin, the fullness hormone the pancreas releases alongside insulin, given as a weekly shot. | A once-weekly amylin drug from Eli Lilly, built to copy the fullness hormone the pancreas releases with insulin, and to act on its receptor more selectively than cagrilintide does. |
| How it works | Long-acting, lipidated analogue of amylin, the satiety hormone the pancreas releases with insulin. It activates amylin receptors and the calcitonin receptor (a non-selective amylin agonist); amylin promotes fullness, slows stomach emptying and holds back glucagon after meals. A fatty-acid chain stretches its half-life to about a week, so it is a weekly shot, usually run beside a GLP-1. Not approved on its own: it is the amylin half of Novo Nordisk's CagriSema. | Once-weekly, long-acting agonist of the amylin receptor, the receptor for amylin, the fullness hormone the pancreas releases with insulin. Unlike cagrilintide, it is selective: it acts far more on amylin receptors than on the calcitonin receptor, a difference Lilly thinks may make it easier on the stomach. The idea is fewer calories through earlier fullness after meals rather than through the GLP-1 pathway. Its half-life of about 14 days keeps blood levels nearly flat across the week. Investigational, from Eli Lilly, in phase 3 since late 2025. |
| Commonly reported | Feeling full sooner and portions shrinking, with nausea or constipation after step-ups and some injection-site reactions. It is not approved on its own. | In trials, fewer cravings, especially for sugar, and less food noise, with nausea and tiredness more likely on the higher doses. It is in phase 3 and not approved anywhere. |
| Studied range | Research range: 0.25–2.4 mg, starting dose 0.25 mg. Studied in research — not a recommendation. | Research range: 1–9 mg, starting dose 3 mg. Studied in research — not a recommendation. |
| How often | Weekly | Weekly |
| Half-life | ~1 week (measured in people: 159–195 hours in a phase 1b trial) | ~14 days (measured in people: phase 1 trials, Bhattachar 2026) |
| Route | SubQ injection | SubQ injection |
| Typical run | Trials run it continuously: 26 weeks in phase 2, 68 weeks in phase 3. Community use is mostly as a weekly add-on to a GLP-1. | Used continuously, once weekly, in its trials: 12 weeks in phase 1 and 48 weeks in phase 2; phase 3 runs about 75 weeks. No trial has tested stopping it. |
| Evidence | Established: clinical trials or FDA-approved use exists | Moderate: animal studies + some human data |
| Common side effects | Nausea, constipation, diarrhea, injection-site reactions | Nausea, fatigue, constipation, diarrhea, vomiting, decreased appetite, hair thinning, injection site reaction |
- Category
- CagrilintideMetabolic & GLP-1
- EloralintideMetabolic & GLP-1
- Also known as
- CagrilintideCagri, AM833, NNC0174-0833
- EloralintideLY3841136, Elora
- What it is
- CagrilintideA long-acting version of amylin, the fullness hormone the pancreas releases alongside insulin, given as a weekly shot.
- EloralintideA once-weekly amylin drug from Eli Lilly, built to copy the fullness hormone the pancreas releases with insulin, and to act on its receptor more selectively than cagrilintide does.
- How it works
- CagrilintideLong-acting, lipidated analogue of amylin, the satiety hormone the pancreas releases with insulin. It activates amylin receptors and the calcitonin receptor (a non-selective amylin agonist); amylin promotes fullness, slows stomach emptying and holds back glucagon after meals. A fatty-acid chain stretches its half-life to about a week, so it is a weekly shot, usually run beside a GLP-1. Not approved on its own: it is the amylin half of Novo Nordisk's CagriSema.
- EloralintideOnce-weekly, long-acting agonist of the amylin receptor, the receptor for amylin, the fullness hormone the pancreas releases with insulin. Unlike cagrilintide, it is selective: it acts far more on amylin receptors than on the calcitonin receptor, a difference Lilly thinks may make it easier on the stomach. The idea is fewer calories through earlier fullness after meals rather than through the GLP-1 pathway. Its half-life of about 14 days keeps blood levels nearly flat across the week. Investigational, from Eli Lilly, in phase 3 since late 2025.
- Commonly reported
- CagrilintideFeeling full sooner and portions shrinking, with nausea or constipation after step-ups and some injection-site reactions. It is not approved on its own.
- EloralintideIn trials, fewer cravings, especially for sugar, and less food noise, with nausea and tiredness more likely on the higher doses. It is in phase 3 and not approved anywhere.
- Studied range
- CagrilintideResearch range: 0.25–2.4 mg, starting dose 0.25 mg. Studied in research — not a recommendation.
- EloralintideResearch range: 1–9 mg, starting dose 3 mg. Studied in research — not a recommendation.
- How often
- CagrilintideWeekly
- EloralintideWeekly
- Half-life
- Cagrilintide~1 week (measured in people: 159–195 hours in a phase 1b trial)
- Eloralintide~14 days (measured in people: phase 1 trials, Bhattachar 2026)
- Route
- CagrilintideSubQ injection
- EloralintideSubQ injection
- Typical run
- CagrilintideTrials run it continuously: 26 weeks in phase 2, 68 weeks in phase 3. Community use is mostly as a weekly add-on to a GLP-1.
- EloralintideUsed continuously, once weekly, in its trials: 12 weeks in phase 1 and 48 weeks in phase 2; phase 3 runs about 75 weeks. No trial has tested stopping it.
- Evidence
- CagrilintideEstablished: clinical trials or FDA-approved use exists
- EloralintideModerate: animal studies + some human data
- Common side effects
- CagrilintideNausea, constipation, diarrhea, injection-site reactions
- EloralintideNausea, fatigue, constipation, diarrhea, vomiting, decreased appetite, hair thinning, injection site reaction
Typical run: Community practice — opinions vary. Not a clinical recommendation.

Model. Individual results vary.
Week by week
Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.
Cagrilintide
- Day 1–28 · 0.25 mg The 0.25 mg start
- Day 29–364 · 0.5 mg 0.5 mg, the second step
- Day 57–364 · 1 mg 1 mg, the middle step
- Day 85–364 · 1.7 mg 1.7 mg, the step before 2.4 mg
- Day 113+ · 2.4 mg 2.4 mg, the phase 3 dose
Eloralintide
- Day 1–28 · 3 mg Fullness first, gently
- Day 29–56 · 6 mg The step where nausea shows up
- Day 57–336 · 6 mg Holding at 6 mg
- Day 57–336 · 9 mg The top dose tested
- Day 85–336 Fewer cravings, quieter food noise
- Day 337+ A long-term medicine, not a course
Questions people ask
How long do cagrilintide and eloralintide last?
The half-life of cagrilintide is ~1 week (measured in people: 159–195 hours in a phase 1b trial). The half-life of eloralintide is ~14 days (measured in people: phase 1 trials, Bhattachar 2026).
How often are cagrilintide and eloralintide taken?
Cagrilintide: weekly. Route: SubQ injection. Eloralintide: weekly. Route: SubQ injection.
How are cagrilintide and eloralintide dosed in research?
The research range for cagrilintide is 0.25–2.4 mg, with a 0.25 mg starting dose. The research range for eloralintide is 1–9 mg, with a 3 mg starting dose. Studied in research — not a recommendation.
What are the common side effects of cagrilintide and eloralintide?
For cagrilintide, the library lists: nausea, constipation, diarrhea, injection-site reactions. For eloralintide: nausea, fatigue, constipation, diarrhea, vomiting, decreased appetite, hair thinning, injection site reaction.